Análisis económico de las vacunas del primer año de vida con componente pertussis en el contexto de la ini-ciativa mundial de erradicación de la poliomielitis en Argentina
| Autor: | Juan Guillermo Lopez, Hugo Dibarboure, Norberto Giglio, Vanesa Castellano, Angela Gentile |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
vacuna contra la tosferina
Bordetella pertussis Reactogenicity biology business.industry Public Health Environmental and Occupational Health poliomielitis First year of life medicine.disease biology.organism_classification Inactivated polio vaccine Poliomyelitis costos y análisis de costos Vaccination Infectious Diseases Environmental health Poliomyelitis eradication medicine Economic analysis esquemas de inmunización business health care economics and organizations |
| Zdroj: | Revista chilena de infectología v.38 n.2 2021 SciELO Chile CONICYT Chile instacron:CONICYT |
| ISSN: | 0716-1018 |
| Popis: | Background Global Polio Eradication Initiative promotes the introduction of inactivated polio vaccine (IPV) in its programs, with withdrawal of Sabin (bOPV). There is no an economic analysis of the investment related to the incorporation of IPV vaccines together with a whole cell Bordetella pertussis vaccine or combined with acellular hexavalent. Aim An economic model that compares different vaccination schemes for the prevention of polio and pertussis in the first year of life was carried out. Methods Four vaccination scenarios for the primary scheme based on Argentina demographic and costs data were developed: - Scenario 1 (base case): two doses of IPV, one dose of bOPV and three doses of pentavalent (DTwP-HepB-Hib) vaccine; - Scenario 2: three doses of IPV plus three doses of pentavalent; - Scenario 3: three doses of hexavalent; - Scenario 4: two doses of hexavalent plus one dose of pentavalent plus IPV. Results The incremental cost based on scenario 1 was USD 3.716.671; 19.696.668 and 14.383.341 for scenarios 2, 3 and 4 respectively. In terms of reactogenicity savings was -14.178.240 compared base case with scenario 3. Discussion Full IPV introduction investment and costs associated were modified according to the type of vaccine and reactogenicity related with the B. pertussis component. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|